Conference appearance and reaffirmed guidance draw fresh focus

Oscar Health (OSCR) is back in the spotlight after management used its appearance at the 47th Annual Raymond James Institutional Investor Conference to reaffirm full year 2026 guidance, underscoring its current expectations for the business.

This reaffirmation gives current and prospective shareholders a clearer view of how management is thinking about the next few quarters at a time when the stock’s recent performance has been mixed.

The reaffirmed guidance comes as the shares trade at US$14.39, with a recent 7 day share price return of 5.34% contrasting with a 90 day share price return decline of 14.19%. At the same time, the 3 year total shareholder return sits at a very large gain and the 5 year total shareholder return remains sharply negative, suggesting long term recovery has been mixed and momentum has recently cooled.

If this guidance update has you rethinking where you look for opportunity in healthcare, it could be a good time to scan 31 healthcare AI stocks as another way to broaden your research list.

With Oscar Health shares at US$14.39, only about 7% below the average analyst target and carrying a mixed rating profile, the key question is whether the current weakness is a mispricing or whether the market already recognises future growth.

Most Popular Narrative: 8.8% Undervalued

Oscar Health’s most followed narrative pegs fair value at about $15.78 versus the last close of $14.39, framing the reaffirmed 2026 guidance against a slightly higher long term target.

The normalization of higher market morbidity through aggressive repricing (double digit rate increases for 2026 already refiled in nearly all markets) and productive regulator engagement increase confidence in future margin recovery and a return to positive earnings.

Curious what sits behind that confidence in margin recovery and earnings power? The narrative leans heavily on revenue growth, rising profitability, and a richer future earnings multiple that is not yet fully reflected in today’s price.

Result: Fair Value of $15.78 (UNDERVALUED)

However, there is still real risk that higher claims costs within ACA markets and potential policy shifts around premium subsidies could pressure future margins and membership growth.

Next Steps

If this all feels finely balanced between risk and reward, now is a good time to look at the numbers yourself and move quickly. Start with 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Oscar Health sits on your watchlist but you want a broader set of opportunities, now is a good time to expand your research before the next move.

• Target consistent payouts by scanning income opportunities through 14 dividend fortresses that focus on companies with higher yielding distributions.
• Hunt for potential mispricings with 47 high quality undervalued stocks, where you can filter for businesses that combine quality fundamentals with a discounted share price.
• Prioritise resilience by running 77 resilient stocks with low risk scores and concentrating on companies that score well on balance sheet strength and lower risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.